Arrowhead shelves one cardiometabolic drug candidate, focuses on another

On Tues­day, Ar­row­head Phar­ma­ceu­ti­cals said it will shift fo­cus to its ex­per­i­men­tal car­diometa­bol­ic drug ploza­sir­an and will de­pri­or­i­tize its work on zo­dasir­an, em­pha­siz­ing the need …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.